As the Food And Drug Administration takes a firmer stance on the health benefit claims of CBD products, companies involved in the cannabis and hemp business have begun kicking off clinical trials and research projects aimed at quantifying the specific effects of cannabidiol.
Following federal approval, this morning British Columbia-based Tilray Inc. (NASDAQ: TLRY) imported a shipment of Good Manufacturing Processes certified CBD in capsule form to the U.S. for upcoming double bind tests.
Those capsules will be utilized in two clinical trials at the NYU School of Medicine looking at potential anti-addictive effects of CBD and methods for treating returning veterans with Post-Traumatic Stress Disorder.
The school’s Professor of Psychiatry, Dr. Michael Bogenschutz, will oversee the first trial with patients suffering from Alcohol Use Disorder alone.
Dr. Charles R. Marmar, the NYU Lucius Littauer Professor and Chair of the Department of Psychiatry, ... read more at: https://grizzle.com/tilray-tlry-cbd-import-nyu-trials/
... read more at: https://grizzle.com/tilray-tlry-cbd-import-nyu-trials/